Congenital Disorder of Glycosylation Type 1a – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

 

Congenital disorder of glycosylation type 1a is an inherited disease characterized by variable developmental delays as well as muscle and bone problems that worsen with age. Individuals with glycosylation disorder type 1a have phosphomannomutase 2 enzyme deficiencies. CDG-Ia is related to deficient phosphomannomutase activity and represents 80% of CDG type I. The enzyme is coded by PMM2, a gene situated in chromosomal segment 16p13. Gastrointestinal and neurologic symptoms predominate in the neonatal period and infancy. The most important features during childhood are hypotonia, ataxia, mental retardation, joint contractures, and pigmentary retinopathy. It is estimated that 20% of patients die during the first year of life due to severe infection, liver insufficiency or cardiomyopathy.

• The prevalence of Congenital disorder of glycosylation type 1a ranges from 1 to 2 cases in 200,000 newborn population in the USA.

 

Thelansis’s “Congenital Disorder of Glycosylation Type 1a Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Congenital Disorder of Glycosylation Type 1a treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of Congenital Disorder of Glycosylation Type 1a across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Congenital Disorder of Glycosylation Type 1a Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Congenital Disorder of Glycosylation Type 1a – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033